Current Report Filing (8-k)
January 07 2020 - 11:58AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 19, 2019
GENEREX
BIOTECHNOLOGY CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-29169
|
|
98-0178636
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S Employer
Identification No.)
|
10102
USA Today Way, Miramar, Florida
|
|
33025
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, including area code: (416) 364-2551
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
November 19, 2019, Omar Gzouli tendered his resignation from the board of directors of Generex Biotechnology Corporation. Mr.
Gzouli indicated that due to his current work schedule, he would be unable to give the proper time in to his service as a Generex
board member .Mr. Gzouli has been reviewed the foregoing 8-K and agrees with the statements contained in this filing pertaining
to the reason for his resignation.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
|
GENEREX BIOTECHNOLOGY
CORPORATION.
|
|
|
Date: November 26, 2019
|
|
/s/ Joseph
Moscato
|
|
|
Joseph Moscato
|
|
|
President and CEO
|